Chronic coronary syndromes

Article written and reviewed by Dr Luca Moretti

Chronic coronary syndromes comprise the clinical manifestations of coronary artery disease outside an acute phase. The concept replaces the idea of “stable coronary artery disease” as a static condition: atherosclerosis, endothelial function, the microcirculation, thrombosis, and myocardial demand change over time even when symptoms remain similar. Patients may present with exertional angina, dyspnea, painless ischemia, ventricular dysfunction, or no symptoms after myocardial infarction or revascularization. Stability describes the clinical moment, not an absence of progression or risk.
The group includes people with suspected coronary artery disease and stable symptoms, patients with an already documented anatomical or functional diagnosis, individuals stabilized after an acute coronary syndrome, and patients with ischemic cardiomyopathy. It also includes forms with non-obstructive arteries in which microvascular dysfunction or vasospasm may cause ischemia; this breadth precludes uniform treatment. Diagnosis must specify phenotype, anatomy, mechanism, ventricular function, and objectives, distinguishing symptom control from event prevention.

The page on chronic coronary syndrome develops the overall clinical framework, whereas stable angina describes reproducible pain and its equivalents. Silent myocardial ischemia concerns objective episodes without recognized symptoms; refractory angina, by contrast, identifies persistent symptoms despite therapy and feasible revascularization. Boundaries may overlap, but each page maintains a different clinical focus. A patient may move from one phenotype to another over the natural history.
Contemporary management addresses three questions: how likely the symptoms are to be coronary, which ischemic mechanism produces them, and what risk of death or events exists independently of symptoms. CCTA, functional imaging, coronary angiography, and invasive physiology are not automatic steps but tools selected to answer a question. Therapy combines lifestyle, control of lipids, blood pressure, and diabetes, an antithrombotic strategy, antianginal drugs, and revascularization when indicated. Follow-up assesses both quality of life and prognostic protection.

Etiology, risk factors, pathogenesis, and pathophysiology

Epicardial atherosclerosis is the most common substrate. Retention of apoB-containing lipoproteins, inflammation, and remodeling produce plaques that may narrow the lumen or grow outward without apparent stenosis. Overall atherosclerotic burden predicts events beyond the individual lesion; smoking, LDL, blood pressure, diabetes, kidney disease, family history, and lipoprotein(a) modulate onset and progression. A nonsevere plaque may cause an acute event, whereas a severe fibrotic stenosis may primarily produce exertional ischemia.
A stenosis limits flow when demand rises, but the relationship between diameter and ischemia is not linear. Length, geometry, diffuse disease, aortic pressure, collateral vessels, and the microcirculation determine effective reserve. FFR and iFR measure the lesion’s hemodynamic impact within the circulation; they do not describe plaque vulnerability and may be influenced by microvascular function. Anatomy is therefore necessary but insufficient to explain symptoms and prognosis.

Microvascular dysfunction reduces coronary flow reserve through structural abnormalities, rarefaction, arteriolar remodeling, or abnormal vasomotor control. It may coexist with epicardial stenoses, persist after PCI, and explain some residual angina. Epicardial or microvascular vasospasm causes dynamic ischemia, often at rest but sometimes during exertion. These mechanisms are particularly important in ANOCA and INOCA and require functional assessment because a “normal” coronary angiogram does not exclude them.
Oxygen demand rises with heart rate, contractility, and wall tension. Hypertension, tachycardia, anemia, hyperthyroidism, and aortic stenosis may lower the anginal threshold without changing the stenosis. Conversely, bradycardia and reduced afterload may improve the balance; the subendocardium is more vulnerable because of greater tension and compression during systole. Physical conditioning reduces demand for a given external workload and improves endothelial function, explaining part of the benefit of rehabilitation.

Ischemia first alters metabolism and perfusion, then relaxation, contractility, and the ECG, and finally causes pain: the so-called ischemic cascade. Duration, intensity, and collateral vessels modify the observable order; in microvascular dysfunction, regional tests may be less sensitive because hypoperfusion is diffuse. Repeated episodes may cause stunning or, in advanced disease, hibernating myocardium with reduced function but residual viability. Revascularizing viable myocardium does not automatically guarantee a prognostic benefit and is assessed in the clinical context.
Plaque vulnerability maintains the link between the chronic phase and an acute event. Inflammation, a thin cap, a lipid core, and mechanical stress promote rupture or erosion; the previous stenosis may have been modest. Statins and risk-factor control reduce events throughout the coronary tree, not merely by lowering the degree of a stenosis. Revascularization removes or bypasses a focal flow limitation but does not replace systemic prevention.

Sex and gender differences influence exposure, presentation, and access to care. Women more often have ANOCA and INOCA, but may also have severe obstructive disease and sometimes receive delayed diagnosis or treatment; men are not protected from microvascular disorders. Pregnancy, menopause, hormonal therapies, and autoimmune disease are considered in context without being used as automatic explanations. An equitable pathway applies the same diagnostic precision to symptoms and risk, avoiding stereotypes.
Systemic inflammation, rheumatic disease, HIV, and cancer treatments may accelerate atherosclerosis or damage the microcirculation. Mediastinal radiotherapy causes ostial, proximal, valvular, and pericardial disease after a long latency; some drugs cause vasospasm, thrombosis, or dysfunction. The oncologic and immunologic history modifies probability and imaging selection. Prevention is coordinated with the specialist to avoid unnecessary interruption of essential therapies.

Classification, pathological anatomy, progression, and phenotypes

Guidelines describe several clinical scenarios: newly suspected coronary artery disease with stable symptoms; heart failure or ventricular dysfunction of possible ischemic origin; the period after an acute syndrome or revascularization; a long-standing diagnosis with or without symptoms; and angina or ischemia with non-obstructive coronary arteries. The scenarios determine different probabilities, tests, and objectives. A classification based only on the presence of pain misses asymptomatic high-risk patients and highly symptomatic patients without obstruction.
Stable angina is predictable in threshold and triggers, generally resolves with rest or nitrate, and may be graded using the Canadian Cardiovascular Society classification. Stability does not mean mild pain: reproducible class III angina may limit daily activities without being acute. A recent change in frequency, duration, or threshold, or onset at rest, requires reassessment for an acute syndrome. Dyspnea may be an equivalent but must be distinguished from heart failure, lung disease, anemia, and deconditioning.

Silent ischemia is documented by ECG, imaging, or metabolic abnormalities in the absence of symptoms perceived during the episode. It may alternate with angina in the same patient and occurs more readily with diabetes, autonomic neuropathy, older age, or previous myocardial infarction. It is not the same as asymptomatic atherosclerosis and does not justify universal stress-test screening. Pretest probability and whether the result can change management determine whether it should be sought.
Refractory angina persists despite maximally tolerated anti-ischemic therapy and indicated, feasible revascularization. Before labeling symptoms refractory, diagnosis, adherence, doses, residual stenoses, grafts or stents, the microcirculation, vasospasm, myocardial bridging, and noncardiac causes must be verified. The modern definition also includes non-obstructive mechanisms. Quality of life is often the dominant problem, but prognostic risk is assessed separately.

The post-infarction or post-revascularization phenotype may be asymptomatic or present with residual angina, heart failure, or arrhythmias. Stent restenosis and thrombosis, progression of other plaques, graft degeneration, and microvascular dysfunction have different timelines and presentations. Imaging at fixed intervals is not automatically indicated in a stable patient if the result would not change therapy. New symptoms or functional deterioration instead reopen anatomical and physiological assessment.
Ischemic cardiomyopathy combines scar, ventricular remodeling, possible hibernating myocardium, and functional mitral regurgitation. Symptoms may be dominated by dyspnea and edema rather than pain; ejection fraction affects prognosis, heart-failure therapy, device indications, and revascularization choice. Viability is one component of the picture and must not be used in isolation to promise recovery.

Chronic coronary artery disease may also be classified by clinical objective: diagnostic confirmation, angina control, prognostic assessment, post-revascularization evaluation, or heart-failure management. The same stenosis is therefore studied using different tools depending on the decision to be made; an anatomical test addresses the presence of plaque, whereas a functional test addresses its effect on flow. Separating the questions reduces testing cascades and makes each result interpretable.
A patient may pass through multiple phenotypes: initial angina, PCI, an asymptomatic period, residual ischemia, heart failure, or an acute event. This longitudinal transition requires diagnoses and medications to be updated without erasing the previous history. Documentation of stents, grafts, function, and non-obstructive mechanisms prevents repetition. Follow-up must recognize when pretest probability has changed, because a remote negative test does not confer indefinite protection.

Clinical manifestations

Typical angina is retrosternal discomfort brought on by exertion or stress and relieved by rest or nitrate. It may radiate to the arms, jaw, neck, back, or epigastrium; heaviness, pressure, and burning are common descriptions. The threshold varies with cold, meals, climbing, wind, and activity after waking. A duration of a few minutes and reproducibility support the diagnosis, but no single feature is sufficient.
Equivalent manifestations include dyspnea, fatigue, reduced capacity, and sometimes nausea or sweating. Women, older adults, and people with diabetes may report less stereotypical symptoms, but the label “atypical” must not preclude a structured assessment. Instantaneous stabbing pain, pain reproducible on palpation, or pain related to movement lowers probability without eliminating it. Reflux, musculoskeletal disease, anxiety, and lung disease may coexist with coronary artery disease.

The history quantifies frequency, duration, threshold, response to medication, and impact on life. A diary and the Seattle Angina Questionnaire make symptom burden measurable and enable response assessment. It is important to ask which activities the patient avoids: apparent absence of angina may result from self-limitation. The CCS class describes limitation due to angina but does not replace functional capacity, frailty, and personal goals.
The examination assesses blood pressure, pulses, murmurs, signs of heart failure, anemia, thyroid disease, and vascular disease. A normal examination is common in stable coronary disease; a third heart sound, crackles, jugular venous distention, or a mitral murmur indicates structural involvement. An aortic murmur modifies the differential diagnosis and test selection. A low ankle-brachial index, carotid disease, and an aortic aneurysm signal systemic atherosclerosis and higher risk.

Signs of destabilization include new pain at rest, rapid crescendo, prolonged duration, reduced response to nitrate, syncope, hypotension, acute edema, or arrhythmias. In these conditions, assessment follows acute coronary syndrome algorithms with ECG and troponin testing, without waiting for an outpatient visit. A slowly worsening threshold may also result from anemia, infection, or nonadherence. The distinction between chronic and acute is clinical and temporal, not based on a single word used by the patient.
In asymptomatic patients, the first manifestation may be myocardial infarction, heart failure, an arrhythmia, or an incidental finding of coronary calcium. Lack of pain does not mean low probability, but neither does it justify indiscriminate functional testing. Risk is estimated from factors, organ damage, and known disease. In diabetes, intensive prevention is necessary irrespective of systematic ischemia screening, which has not shown a generalized outcome benefit.

In older adults, frailty, sarcopenia, and osteoarthritis may prevent the anginal threshold from being reached and make important disease appear silent. Confusion, a fall, or loss of autonomy may accompany acute events but have many alternatives; functional and cognitive assessment complements the history. Objectives prioritize independence and tolerability without denying effective procedures solely because of chronological age.
Athletes and physically active people may notice a decline in performance before pain; in sedentary people, capacity limited by other causes may conceal ischemia. Occupational workload, sexual activity, and caregiving responsibilities are components of the real threshold. An exercise prescription translates risk into permitted activity. Generic instructions such as “avoid exertion” increase deconditioning and do not replace risk stratification.

Investigations and diagnosis

Initial assessment includes the history, examination, ECG, complete blood count, kidney function, glucose or HbA1c, and lipid profile. Troponin is indicated when symptoms or timing suggest an acute event, not as a routine test for every chronic pain. Echocardiography measures ejection fraction, wall motion, valves, and pressures. Clinical probability of obstructive coronary artery disease integrates age, sex, symptoms, and modifiers; contemporary models avoid the overestimation of older scores.
Coronary CCTA is effective for excluding stenoses and describing plaques, especially with low or intermediate probability and good expected image quality. Extensive calcium, arrhythmia, obesity, kidney function, allergy, and the ability to control heart rate influence selection. A good-quality negative study markedly reduces the probability of obstructive epicardial disease. Intermediate stenoses may require FFR-CT, stress imaging, or coronary angiography according to symptoms and risk.

Stress echocardiography, SPECT, PET, and CMR assess inducible ischemia, function, and risk. PET and quantitative CMR can measure flow and reserve, which is useful in diffuse or microvascular disease; stress echocardiography does not use radiation but depends on the acoustic window and operator. Selection considers local expertise, contraindications, and the clinical question. Exercise ECG retains value for symptoms, capacity, blood pressure, and arrhythmias when interpretable, but has lower accuracy for diagnosing stenosis.
Invasive coronary angiography is indicated with very high probability, severe refractory symptoms, high noninvasive risk, significant dysfunction, or uncertainty requiring an interventional decision. Intermediate stenoses are assessed with FFR or iFR before PCI, except when physiology is inappropriate. OCT and IVUS define plaque and optimize stent implantation but do not always replace physiology. Without obstructions, CFR, microvascular resistance, and acetylcholine may identify the ANOCA/INOCA endotype.

Prognostic stratification integrates anatomy, ischemia, ventricular function, symptoms, and comorbidities. Left main disease, complex multivessel disease, extensive ischemia, and reduced ejection fraction may change the strategy; a small ischemic area with normal function has different implications. Coronary calcium quantifies atherosclerotic burden but does not by itself demonstrate a stenosis responsible for symptoms. Biomarkers and imaging are requested when they change decisions, avoiding a chain of incidental tests.
The differential diagnosis includes valvular disease, nonischemic heart failure, cardiomyopathies, pericardial disease, aortic disease, pulmonary embolism, reflux, and chest-wall disorders. The presence of plaque does not prove that every pain is angina; absence of stenosis does not prove that pain is noncardiac. A complete diagnosis states the degree of certainty and mechanism. When tests and symptoms disagree, quality, probability, the microcirculation, and alternative diagnoses are reassessed before similar tests are repeated.

Every method carries the possibility of false or indeterminate results. Low probability increases false positives; calcium and motion reduce CT quality; attenuation and balanced ischemia limit SPECT; a poor acoustic window limits echocardiography; artifacts and contraindications affect CMR. The report must state quality and limitations, not merely a binary conclusion. When a result does not fit the clinical picture, the next choice should address the specific limitation.
Kidney function influences the use of iodinated contrast and gadolinium but does not justify automatic avoidance. Appropriate hydration, contrast reduction, and selection of methods without contrast limit risk; in advanced disease, the type of gadolinium is considered. Radiation risk is cumulative and particularly relevant in younger patients, although it remains lower than the risk of failing to diagnose a serious condition when testing is indicated. Benefit and harm are compared individually.

Treatment and prognosis

Therapy has two separate objectives: reducing cardiovascular events and improving symptoms and function. Smoking cessation, prescribed physical activity, a Mediterranean-style diet, weight management, sleep, and rehabilitation affect risk and quality of life. Support must be concrete: pharmacotherapy for smoking cessation, an exercise program, and repeated target measurements. Stress, depression, and social vulnerability affect adherence and are addressed without automatically attributing pain to them.
Reduction of atherogenic lipoproteins uses a high-intensity statin and, if the target is not reached or risk requires it, ezetimibe, a PCSK9 inhibitor, or other therapy according to guidelines. Blood pressure and diabetes are treated with drugs that provide cardiovascular benefit when indicated. ACE inhibitors or angiotensin receptor blockers are particularly useful with hypertension, diabetes, kidney disease, ventricular dysfunction, or heart failure. Influenza, adherence, interactions, and tolerance are reassessed, avoiding labeling a patient “intolerant” without systematic verification.

Long-term antiplatelet therapy is generally indicated in known atherosclerotic coronary disease, balancing bleeding risk. After PCI, duration and combinations depend on presentation, stent, and the need for an anticoagulant. Indefinite DAPT is not routine; in patients with atrial fibrillation, an anticoagulant replaces or is temporarily combined with antiplatelet agents according to precise timelines. Gastroprotection, kidney function, anemia, and previous bleeding are part of the prescription.
For angina, beta-blockers, calcium channel blockers, long-acting nitrates, ranolazine, ivabradine, or other drugs are selected according to heart rate, blood pressure, ventricular function, rhythm, and mechanism. No rigid hierarchy applies to every patient. Sublingual nitrate treats the episode and may be used before predictable exertion, with instructions to sit down and seek help if pain persists. Therapy is titrated to symptoms and effects, avoiding iatrogenic bradycardia or hypotension.

Revascularization is recommended for limiting symptoms despite therapy or for specific anatomical or functional conditions with possible prognostic benefit. PCI and bypass surgery are compared according to complexity, diabetes, function, surgical risk, and preferences in a Heart Team when needed. In stable disease, PCI does not replace preventive therapy, and its most consistent benefit is symptomatic. Physiological demonstration avoids procedures on stenoses that do not limit flow.
Follow-up monitors symptoms, capacity, blood pressure, lipids, glucose, kidney function, adherence, and new events. It does not require automatic annual imaging in a stable patient; new symptoms, heart failure, arrhythmias, or a change in risk guide investigations. Prognosis depends more on ejection fraction, anatomy, plaque burden, comorbidities, and successful prevention than on angina frequency alone. Shared goals and a written plan reduce fragmentation among the physician, cardiologist, and rehabilitation team.

Adherence improves when patients understand the purpose of each drug. A treatment plan distinguishes prognostic, antianginal, and temporary drugs and states DAPT duration and nitrate management. Combination pills and synchronized dosing may reduce burden; adverse effects are sought before they lead to autonomous discontinuation. Shared decision-making does not mean transferring an unexplained choice to the patient, but comparing benefits, risks, and preferences using understandable numbers.
Return to work, driving, travel, and sexual activity is based on clinical stability, functional capacity, and applicable regulations. Rehabilitation can provide supervised assessment and address fear or occupational barriers; recommendations change after myocardial infarction, PCI, bypass surgery, and heart failure and are updated. Effective follow-up is not limited to laboratory values but assesses whether the patient has regained the life they consider meaningful.

Complications

The most feared complication is progression to acute coronary syndrome because of plaque rupture or erosion. Risk is not confined to the stenosis causing angina and may emerge after long stable periods; pain at rest or crescendo pain, troponin changes, and ECG abnormalities require renewed assessment. Lipid prevention, smoking cessation, and blood-pressure control reduce residual risk, whereas elective PCI does not “immunize” against events from other plaques.
Repeated infarctions and ischemia may produce ischemic cardiomyopathy, heart failure, mitral regurgitation, and remodeling. Heart-failure therapy is added to coronary management; revascularization is selected according to anatomy, symptoms, function, and risk. Congestion and kidney disease form a cycle that complicates dosing and prognosis. Reassessing ejection fraction after optimization supports appropriate decisions about defibrillation and resynchronization.

Atrial and ventricular arrhythmias result from ischemia, scar, dysfunction, and comorbidities. Atrial fibrillation increases embolic risk and changes antithrombotic therapy; ventricular tachycardia and syncope require assessment of scar and correctable ischemia. Bradycardia may be spontaneous or drug-induced and limit beta-blockers, ivabradine, and certain calcium channel blockers. Prolonged monitoring is guided by symptoms and findings, not used as indefinite screening.
Bleeding is a complication of antithrombotic prevention and may negate its benefit. Age, kidney disease, anemia, previous hemorrhage, and the need for an anticoagulant require individualized selection and duration. Stopping therapy autonomously after stent implantation may cause thrombosis; continuing it without reassessment may cause hemorrhage. The plan must state duration, perioperative management, and whom to contact before stopping medication.

Persistent angina may progress to disability, deconditioning, depression, and job loss. Repeated angiography without identifying microvascular dysfunction, vasospasm, or noncardiac causes exposes patients to procedures without benefit. A multidisciplinary service may integrate ischemic therapy, rehabilitation, pain management, and psychological support. Quality of life is a legitimate clinical outcome and must be measured without confusing it with mortality risk.
Atherosclerotic disease is systemic: stroke, peripheral artery disease, aortic aneurysm, and kidney disease share risk factors and affect prognosis. The onset of claudication, TIA, or declining kidney function requires a coordinated strategy; polypharmacy increases interactions, hypotension, and falls, especially in frail older adults. Deprescribing unnecessary drugs while preserving prognostic therapies requires periodic review, not merely reducing the medication count.

Acute kidney injury may follow shock, congestion, contrast exposure, or medication and increases event risk. Prevention corrects volume status, limits nephrotoxins, and adjusts doses. Attributing every creatinine rise to contrast may delay necessary testing; chronic kidney disease modifies antithrombotic therapy and revascularization choice. Cardiologists and nephrologists coordinate decisions in advanced cases.
Comorbidities and frailty may lead to polypharmacy, orthostatic hypotension, and falls. Deprescribing means removing treatments without an indication, not indiscriminately withdrawing prognostic drugs. Doses are adapted to kidney and liver function, weight, and objectives. A fall requires assessment of blood pressure and rhythm as well as neurological or environmental causes. Medication safety is a component of long-term prognosis.